Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease
A 6-Month Prospective, Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Adaptive-Trial-Design Study to Evaluate the Safety and Efficacy of 80mg b.i.d Ladostigil in Patients With Mild to Moderate Probable Alzheimer's Disease
Sponsor: Avraham Pharmaceuticals Ltd
Listed as NCT01354691, this PHASE2 trial focuses on Alzheimer's Disease and Cognitive Impairment and remains completed. Sponsored by Avraham Pharmaceuticals Ltd, it has been updated 9 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Aug 2020 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Feb 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Avraham Pharmaceuticals Ltd
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Algorta, Spain , Barcelona, Spain , Belgrade, Serbia , Graz, Austria , Hamburg, Germany , Horn, Austria , Linz, Austria , Pula, Croatia , Salt, Spain , Schwerin, Germany and 4 more locations